Trial · NCT03022747
Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
NCT03022747, Phase 2, Unknown, Vastra Gotaland Region
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol. Trials, record NCT03022747. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03022747
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
- NCT number
- NCT03022747
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Vastra Gotaland Region
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood
- Interventions
- Allopurinol, Standard treatment
- First posted
- 2017-01-16
- Last updated
- 2017-01-16
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-thioguanine (6TG) levels in erythrocytes | Up to week 25 | The fraction of patients with 6TG levels over 200 nmol/mmol Hb at week 13 and 25 (ie after 12 weeks standard and allopurinol treatment respectively) |
| Secondary | Mean level of 6-thioguanine | Up to week 25 | The mean level of 6TG at week 13 and 25 |
| Secondary | Mean level of DNA-incorporated thioguanine (DNA-TGN) | Up to week 25 | The mean level of DNA-TGN at week 13 and 25 |
| Secondary | Mean level of 6-methylmercaptopurine (6MMP) | Up to week 25 | The mean level of 6MMP at week 13 and 25 |
| Secondary | Mean levels of platelets | Up to week 25 | Comparison of weighted mean of platelets in the treatment phases |
| Secondary | Mean levels of hemoglobin | Up to week 25 | Comparison of weighted mean of hemoglobin in the treatment phases |
| Secondary | Mean levels of absolute neutrophil count (ANC) | Up to week 25 | Comparison of weighted mean of ANC in the treatment phases |
| Secondary | Mean levels of white blood cells (WBC) | Up to week 25 | Comparison of weighted mean of WBC in the treatment phases |
| Secondary | Glutamate pyruvate transaminase (GPT) | Up to week 25 | Comparison of weighted means of serum GPT in the treatment phases |
| Secondary | Bilirubin | Up to week 25 | Comparison of weighted means of serum bilirubin in the treatment phases |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03022747
GET https://conductscience.org/api/trials/v1/NCT03022747/registered